Compare Amgen, Inc. (AMGN) vs eBay Inc (EBAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs eBay Inc — how do they compare? Amgen, Inc. trades at $413.07 (market cap $225.71B), while eBay Inc trades at $106.26 (market cap $47.93B). The key difference: Amgen, Inc. is far larger — about 4.7× eBay Inc's market cap, and Amgen, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| AMGN | EBAY | |
|---|---|---|
Market Cap | $225.71B | $47.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $118.96 |
52-Week Low | $271.18 | $79.41 |
Enterprise Value | $269.02B | $51.75B |
Dividend Yield | 2.42% | 1.15% |
Volume | — | 5,186,418 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
EBAY trades at $111.98, up 1.67% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals, including a net income margin of 18.57% and ROE of 47.38%, supported by revenue growth to $11.10B in 2025. Recent news highlights potential partnership talks with GameStop after a withdrawn $56B bid, adding volatility but strategic interest.
Outlook is positive with a consensus price target of $119.85, indicating ~7% upside, driven by earnings momentum and focus category growth. Risks include competitive pressures in e-commerce and market sensitivity to merger speculation. Investors may find value in sustained profitability and analyst buy ratings, though monitor execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →
